HomeNDC LookupRxCUI directory › RxCUI 2629351

Pirtobrutinib 50 MG Oral Tablet — RxCUI 2629351

RxNorm drug concept · Semantic clinical drug
RxCUI 2629351 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 3 package NDCs Snapshot Jul 14, 2026

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2629351
Official namePirtobrutinib 50 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped2
Package NDCs mapped3
Reported Medicaid activity (SDUD)143 prescriptions · 3 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Pirtobrutinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Jaypirca is used for two types of blood cancer — mantle cell lymphoma (MCL) and chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) — specifically when the disease...
  • What exactly is Jaypirca treating, and why is it being prescribed to me instead of other options?
  • You should take it at the same time every day — consistency matters more than the specific hour. The good news is you can take it with or without food, so you can fit it into your...
  • Does it matter what time of day I take Jaypirca, or whether I take it with food?
📖 Read our full Pirtobrutinib guide →

🕸️ Concept Web — How Pirtobrutinib 50 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Pirtobrutinib 50 MG Oral Tablet RxCUI 2629351

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Pirtobrutinib 2629338
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Jaypirca 2629344
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Pirtobrutinib Oral Tablet 2629342
    • Pirtobrutinib Oral Product 2629340
    • Pirtobrutinib Pill 2629341
    • Pirtobrutinib Oral Tablet [Jaypirca] 2629348
    • Jaypirca Oral Product 2629346
    • Jaypirca Pill 2629347
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Pirtobrutinib 50 MG SCDC · 2629350
  • Pirtobrutinib Oral Tablet SCDF · 2629342
  • Pirtobrutinib Oral Product SCDG · 2629340
  • Pirtobrutinib Pill SCDG · 2629341

Brand-Name Concepts

  • Pirtobrutinib 50 MG Oral Tablet [Jaypirca] SBD · 2629353
  • Pirtobrutinib 50 MG [Jaypirca] SBDC · 2629352
  • Pirtobrutinib Oral Tablet [Jaypirca] SBDF · 2629348
  • Jaypirca Oral Product SBDG · 2629346
  • Jaypirca Pill SBDG · 2629347
  • Jaypirca BN · 2629344

📦 FDA Products & Package NDCs

2 products · 3 package NDCs
3 package NDCs map to RxCUI 2629351 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00002-6902-30 30 TABLET, COATED in 1 BOTTLE (0002-6902-30) JAYPIRCA Eli Lilly and Company 2023-01-27
00002-7026-60 60 TABLET, COATED in 1 BOTTLE (0002-7026-60) JAYPIRCA Eli Lilly and Company 2023-01-27
00002-7026-99 30 TABLET, COATED in 1 BOTTLE (0002-7026-99) JAYPIRCA Eli Lilly and Company 2023-02-15
Observed labelers: Eli Lilly and Company (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.